Zevra Therapeutics (ZVRA) Set to Announce Quarterly Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) is scheduled to announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The company had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. During the same period in the prior year, the firm posted ($0.15) EPS. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Trading Down 0.9 %

Shares of Zevra Therapeutics stock traded down $0.08 on Tuesday, reaching $8.47. 237,769 shares of the company traded hands, compared to its average volume of 535,584. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. The company has a 50 day moving average of $7.77 and a 200 day moving average of $6.24. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.95.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ZVRA shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a research report on Friday, October 11th. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, September 18th. Roth Mkm raised their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Finally, Guggenheim started coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average price target of $20.83.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.